Published in final edited form as:

J Breath Res. 2014 March ; 8(1): 016003. doi:10.1088/1752-7155/8/1/016003.

Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties

Anton Amann^{1,2,4}, Pawel Mochalski¹, Vera Ruzsanyi^{1,2}, Yoav Y Broza³, and Hossam Haick^{3,4}

¹Breath Research Institute, Leopold-Franzens University of Innsbruck, 6850 Dornbirn, Austria

²Department of Anesthesiology and Critical Care Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria

³The Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology, Haifa 3200003, Israel

Abstract

The current review provides an assessment of the exhalation kinetics of volatile organic compounds (VOCs) that have been linked with cancer. Towards this end, we evaluate various physicochemical properties, such as ‘breath:air’ and ‘blood:fat’ partition coefficients, of 112 VOCs that have been suggested over the past decade as potential markers of cancer. With these data, we show that the cancer VOC concentrations in the blood and in the fat span over 12 and 8 orders of magnitude, respectively, in order to provide a specific counterpart concentration in the exhaled breath (e.g., 1 ppb). This finding suggests that these 112 different compounds have different storage compartments in the body and that their exhalation kinetics depends on one or a combination of the following factors: (i) the VOC concentrations in different parts of the body; (ii) the VOC synthesis and metabolism rates; (iii) the partition coefficients between tissue(s), blood and air; and (iv) the VOCs’ diffusion constants. Based on this analysis, we discuss how this knowledge allows modeling and simulating the behavior of a specific VOC under different sampling protocols (with and without exertion of effort). We end this review by a brief discussion on the potential role of these scenarios in screening and therapeutic monitoring of cancer.

Keywords

volatile organic compound; blood solubility; fat solubility; exhalation kinetics; biomarker

1 Introduction

1.1 Background

Volatile organic compounds (VOCs) have been found in breath, blood [1], headspace of cancer cells [2–10], and in headspace of resected cancer tissues [11]. Exhaled breath, which may change its chemical signature depending on the physiological or pathophysiological

⁴Authors to whom any correspondence should be addressed. anton.amann@i-med.ac.at and hhossam@technion.ac.il.

state of disease [12–24], is considered as one of the most fascinating body fluids/sources. Sampling of breath is non-invasive and can be used for screening, at an intensive care unit (ICU) [25, 26], during surgery [27–29], or monitoring pre- and post-surgery [30]. Volatile compounds that do not appear normally in exhaled breath can be used for detection of bacterial or fungal infection in the lungs [31–35]. Also hydrogen and methane [36] are produced by bacteria in the gut, and show high concentrations in persons with fructose or lactose malabsorption after ingestion of these carbohydrates [37, 38]. Other VOCs appear after ingestion of drugs, such as 3-heptanone during valproate therapy [39]. ^{13}C -labeled compounds such as ^{13}C -uracil, ^{13}C -dextromethorphan or ^{13}C -pantoprazol are specifically administered to measure enzyme activity through the respective potential to metabolize these precursors with production of $^{13}\text{CO}_2$ measured in exhaled breath [40–45]. As indicated earlier in the introduction, VOCs do not only appear in exhaled breath, but also in skin emanations [46, 47], urine [48], blood [1] and saliva [49]. In addition to VOCs, also small inorganic molecules like hydrogen, nitric oxide [50–61] or carbon monoxide [62] are most interesting. Another most interesting application of VOCs is their use in search operations [63, 64]. The potential of VOCs and of breath analysis for clinical diagnosis and therapeutic monitoring is enormous, even though at the present stage there are only very few breath tests which have got approval by FDA or by the European Medicines Agency (EMA). In particular, no breath tests based on endogenously produced volatile biomarkers for cancer are FDA- or EMA-approved.

In spite of the promising aspects of the VOCs as disease biomarkers, they are still premature in the field of cancer. One of the main reasons for this pre-maturity could be attributed to the lack of standardization and to the poor knowledge of the biochemical pathways and exhalation kinetics of the cancer-related VOCs. The standardization aspects and the biochemical pathways of the cancer-related VOCs were presented and discussed in earlier papers [18, 65–67]. In the present review, we focus on the discussion of the exhalation kinetics of the cancer-related VOCs. The exhalation kinetics can be determined by actual *real-time* measurements under different conditions [68–76] or by simulation of the flow of some compound within the body [70, 77–83]. With this in mind, we present a list of 112 tentative cancer-related VOCs published in the literature during the last decade. Then, we classify the 112 cancer-related VOCs with respect to their ‘fat-to-blood’ and ‘blood-to-air’ partition coefficients and show how these partition coefficients provide estimation on the relative concentrations in alveolar breath, blood and the fat compartment of the human body. Based on the generated ensemble of the physicochemical data, we discuss how the balance between all of these factors determines the *exhalation kinetics* of cancer VOCs.

1.2 Exhalation kinetics of cancer VOCs

To illustrate the exhalation kinetics of cancer VOCs, we present isoprene as a representative example. Isoprene is the most prominent hydrocarbon in exhaled breath, appearing at ~100 ppb in healthy persons who do not exert any effort [1, 84]. In humans it is believed to be synthesized in the mevalonate pathway [85–87]. It can be measured in *real-time* during an experiment performed at a stationary bicycle [69, 79, 82] or even during sleep [68, 72].

Recently, it was shown that isoprene appears at lower concentrations in exhaled breath of lung cancer [88] and breast cancer patients [89], compared to healthy volunteers. So far, this result is corroborated by the observation that the decrease in concentration of isoprene is correlated with the immune activation as measured by the neopterin concentration in blood [90]. While these findings offer isoprene as a potential cancer biomarker, it is important to know that the concentration of isoprene depends very much on the specific sampling protocol [69–72, 78, 81, 82, 91]. In either case, the clear isoprene's *in-situ* signals achieved by on-line mass-spectrometry techniques make it an ideal candidate for the investigation of cancer-related VOC exhalation kinetics.

Figure 1 shows the output of isoprene (in nmol L⁻¹) during an experiment with a healthy volunteer on a stationary bicycle. For the sake of comparison, the output of acetone (in arbitrary units) and CO₂ (in L min⁻¹) are presented on the same figure, too. The specific investigations of isoprene and acetone have the advantage that the respective concentrations in exhaled breath are high (~100 and ~400 ppb, respectively), which makes measurement and demarcation of exhaled concentrations versus inhaled concentrations comparatively easy. The protocol of this experiment changes between rest phases and 75 W workload pedaling phases. During the first pedaling phase, the output of isoprene increases by a factor of ~10, and subsequently decreases exponentially (still during pedaling phase), with a further decrease back to the baseline concentration during the rest phase. When the volunteer starts to pedal again, the increase in isoprene output is much smaller than during the first pedaling phase. After another rest phase, resumption of the pedaling increases the isoprene output, but at a rather low level. It takes approximately 2 h to resynthesize isoprene in the body and to fill up the isoprene stores in such a way that the huge increase in isoprene output by a factor of ~10 appears again. Putting these findings in a more specific perspective, it is likely that isoprene is produced and stored in the periphery of the human body, probably in the muscles [79, 91]. During exertion of an effort, the blood flow through the muscles increases and leads to transport of isoprene from the muscles to the lungs, where it is exhaled. The exponential decay of isoprene output (still during pedaling phase) is a consequence of the depletion of isoprene in the muscles. During the rest phase, the blood flow through the muscles goes back to baseline and so does the isoprene concentration. It is important to note in this context that the increase of concentration in breath during exertion of an effort indicates that the specific choice of the breath sampling protocol (e.g., quietly sitting, standing, after a period of rest, etc) is of great importance for both healthy and cancer states [92]. Indeed, different sampling protocols may result in very different isoprene concentrations (up to a factor of ~5). We expect that a similar situation is true for many VOC cancer markers [70].

To get a more thorough look on the exhalation kinetics of VOCs, it is important to know which VOCs behave according to the *Farhi equation* [93]:

$$C_{\text{alveolar}} = \frac{C_{\text{v}}}{\lambda_{\text{b:a}} + \dot{V}_{\text{A}} / \dot{V}_{\text{Q}}} \quad (1)$$

The Farhi equation is a first very important step in modeling of the exhalation kinetics [69–72, 78, 80–82, 91]. This equation relates the alveolar concentration (C_{alveolar}) of a VOC to the concentration in mixed venous blood (C_{v}). As seen in this equation, a *decrease* in the concentration during exertion of an effort happens because the alveolar ventilation ($\dot{V}_A$) usually increases more strongly than the cardiac output ($\dot{V}_Q$). An example of a compound that decreases in concentration during effort (in line with Farhi's equation) is *butane* [70].

An important physicochemical constant in the Farhi equation is the 'blood:air' partition coefficient ($\lambda_{b:a}$). For isoprene, this partition coefficient is approximately $0.95 \text{ (mol L}^{-1}) / \text{(mol L}^{-1})$ [94, 95]. This means that the concentration of isoprene in blood is ~95% of the concentration in alveolar air. Incidentally, the 'blood:air' partition coefficient can be quite different from the 'water:air' partition coefficient ($\lambda_{w:a}$) at 37 °C. In case of isoprene, the $\lambda_{w:a}$ is approximately 0.28. The reason for this difference is that blood contains lipids, which take up a larger amount of isoprene than water.

Another important physicochemical constant is the 'fat:blood' partition coefficient ($\lambda_{f:b}$). For isoprene, this $\lambda_{f:b}$ is approximately $82.0 \text{ (mol L}^{-1}) / \text{(mol L}^{-1})$ [96]. This means that the equilibrium concentration of isoprene in fat is about 82 times the concentration of isoprene in blood. For an isoprene concentration of 150 ppb ($\sim 5.8 \times 10^{-9} \text{ mol L}^{-1}$) in alveolar air, the estimated equilibrium concentration in blood is $\sim 5.5 \times 10^{-9} \text{ mol L}^{-1}$ ($= 0.95 \times 5.8 \times 10^{-9} \text{ mol L}^{-1}$) and the estimated concentration in fat is $4.5 \times 10^{-7} \text{ mol L}^{-1}$ ($= 82 \times 5.5 \times 10^{-9} \text{ mol L}^{-1}$).

For a 70 kg person of 1.80 m height, the volume of blood is ~6 L and the amount of fat tissue is estimated to be 12.78 L [97]. In 6 L of blood and 12.78 L of fat, we estimate the amount of isoprene to be $\sim 3.3 \times 10^{-8} \text{ mol}$ ($= 6 \times 5.5 \times 10^{-9} \text{ mol}$) and $\sim 5.8 \times 10^{-6} \text{ mol}$ ($= 12.78 \times 4.5 \times 10^{-7} \text{ mol}$), respectively. Hence the amount of isoprene in fat is estimated to be ~175 times the amount in blood. With this in mind, it is reasonable to claim that the exhalation kinetics of cancer-related VOCs depends on the concentration of the respective VOC in different compartments of the body, on the partition coefficients between the different compartments (e.g., $\lambda_{b:a}$ and on the fat:air partition coefficient $\lambda_{f:a}$), and on the diffusion kinetics between different compartments. In the following section, we will present ways to obtain each of these parameters and discuss the inter-relationship between these parameters as well as with the exhaled VOC-related cancer.

2 Estimating the $\lambda_{b:a}$ and $\lambda_{f:b}$

For the majority of VOCs of interest, the $\lambda_{b:a}$ and $\lambda_{f:b}$ have not been measured. Nevertheless, a number of papers present relevant data on $\lambda_{b:a}$ and $\lambda_{f:a}$ of VOCs [94, 95, 98–106]. In addition, the $\lambda_{b:a}$ of many hydrocarbons can be estimated based on the respective $\lambda_{b:a}$ of similar (but not identical) alkanes and isoalkanes which have been investigated in [95]. Finally, one may estimate $\lambda_{b:a}$ using the formula given by Poulin and Krishnan [107]:

$$\lambda_{b:a} = \lambda_{o:w} \lambda_{w:a} (a + 0.3b) + \lambda_{w:a} (c + 0.7b). \quad (2)$$

Here, $a \approx 0.0033$ is the fraction of neutral lipids in the blood, $b \approx 0.0024$ is the fraction of phospholipids in the blood, and $c \approx 0.82$ is the fraction of water in the blood. The octanol:water partition coefficients ($\lambda_{o:w}$) can be compiled from Scifinder (<https://scifinder.cas.org>), whereas the water:air partition coefficients ($\lambda_{w:a}$; Henry's constants) at 25 °C can be taken from the compilation of Sander [108] or estimated by the EPI Suite™ software developed at the US environmental protection agency (EPA, <http://www.epa.gov/opptintr/exposure/pubs/episuitedi.htm>). Otherwise, $\lambda_{w:a}$ can be estimated by use of surrogate compounds, for which $\lambda_{w:a}$ is known, with correction by the quotient of the respective vapor pressures (of the compound in question and its surrogate compound). Furthermore, in order to estimate the Henry constants at 37 °C, the derivative $d\ln(\lambda_{w:a})/d(1/T)$ as given in the compilation by Sander [108] can be used, or the corresponding enthalpy of vaporization (H_{vap}) divided by the gas constant, R .

Similar to the $\lambda_{b:a}$, one may estimate $\lambda_{f:a}$ using the method of Poulin and Krishnan [107], given by the equation:

$$\lambda_{f:a} = \lambda_{o:w} \lambda_{w:a} (A + 0.3B) + \lambda_{w:a} (C + 0.7B). \quad (3)$$

Here, $A \approx 0.798$ is the fraction of neutral lipids in the adipose tissue (fat), $B \approx 0.002$ is the fraction of phospholipids in the adipose tissue, and $C \approx 0.15$ is the fraction of water in the adipose tissue.

3 Partition coefficients of cancer-related VOCs

During the past decade, some 112 tentative cancer VOCs in exhaled breath have been reported [7, 30, 67, 109–121]. There were 36 hydrocarbons, 7 alcohols, 8 aldehydes, 2 acids, 12 ketones, 12 aromatic compounds, 2 heterocycles, 2 nitriles, 5 terpenes, 7 esters, 2 ethers, 1 sulfide, 2 halogenated compounds, and 15 compounds from other chemical classes. Examples of hydrocarbons among this list of 112 VOCs are 2-methyl-propane (CAS 75-28-5) or 5-methyl-tridecane (CAS 25117-31-1). Example of an alcohol is 1-octen-3-ol (CAS 3391-86-4). Examples of aldehydes are pentanal, hexanal, octanal and nonanal. An example for a ketone is 6-methyl-5-hepten-2-one (CAS 110-93-0). An example of an aromatic compound is benzophenone (CAS 119-61-9). An example of a terpene is 'trans-caryophyllene' (CAS 87-44-5). In addition, also biomarkers in exhaled breath condensate have been published [122].

The 112 cancer VOCs in exhaled breath could be considered as being on an equal footing in exhaled breath. Nevertheless, the very different blood:air partition coefficients ($\lambda_{b:a}$) imply that the respective concentrations in blood are rather different, even if the concentration in breath would be the same. Each of the mentioned 112 compounds can be looked upon from many different viewpoints. Here are a few examples:

- 2-Methyl-propane (CAS 75-28-5) commonly appears in human breath, in smokers and non-smokers [123]. It is also released by *Streptococcus pneumonia* [31]. It has been suggested as volatile biomarker for breast cancer in exhaled breath [111].

- 5-Methyl-tridecane (CAS 25117-31-1) has been suggested to be a volatile biomarker of breast cancer [111] and belongs to the class of monomethylated hydrocarbons, which were proposed to be used in the ‘breath methylated alkane contour’ (BMAC) for detection of cancer and other diseases [124–130].
- Benzophenone (CAS 119-61-9) was observed in the context of feces [131], axillary sweat [132] and saliva [133] and was suggested as a volatile biomarker for lung cancer [134].
- Trans-Caryophyllene (CAS 87-44-5) has been observed on the surface of juicy grapefruits [135], in feces [131], skin emanations [133], human breast milk and saliva [133, 136].
- 6-Methyl-5-hepten-2-one (CAS 110-93-0) is produced on skin by degradation of squalene (and, in particular so during the influence of ozone). This compound is, for example, observed when healthy volunteers sit in a chamber so that the skin emanations are collected and observed in the chamber indoor air. There are three volatiles, acetone, 6-methyl-5-hepten-2-one, and acetaldehyde, which exhibit especially high emission rates through skin exceeding $100 \text{ fmol} \times \text{cm}^{-2} \times \text{min}^{-1}$ without ozone influence [137]. Interestingly, 6-methyl-5-hepten-2-one has recently been observed in exhaled breath of gastric cancer patients [121].

Figure 2 presents the estimated values for the negative logarithm of the blood:air partition coefficients, viz. $-\log(\lambda_{b:a})$. These $\lambda_{b:a}$ are distributed over 12 orders of magnitude. Hence, if the concentrations of the cancer VOCs would be equal in exhaled breath—e.g., at 1 ppb—their concentrations in blood would be very different and also be distributed over 12 orders of magnitude. An analogous situation holds for the $\lambda_{f:b}$ (see figure 3). Similarly as above, if the concentrations of the cancer VOCs would be equal in exhaled breath—e.g., at 1 ppb—their concentrations in fat would be very different and be distributed over 8 orders of magnitude. For this reason when studying VOC concentrations in cancer and relating them to potential metabolic pathways one should estimate the blood/tissue concentration and by these validate the underline metabolic assumption. That is, elevated concentrations in the breath of a certain molecule will not necessary reflect the same magnitude of elevation in the tissue.

The fact that VOC cancer biomarkers vary in concentration over many orders of magnitude is most surprising, and should change the way we look at these compounds. Typically, a high $\lambda_{f:b}$ (as, e.g., for 3-methyl-hexane) will lead to high concentration of the respective volatile compound in lipid membranes (e.g., in endothelial cells demarcating the blood vessels). High concentrations within the lipid membranes may change their permeability properties. It can be expected, that lipophilic volatiles bear considerable influence on pathophysiology of disease.

The fact that these cancer-related VOCs have very different physicochemical properties is expected to be an advantage. The different $\lambda_{b:a}$ and $\lambda_{f:b}$ imply that the concentrations in different compartments (blood, fat, muscle, etc) are very different. As a consequence, the

exhalation kinetics can be expected to be different. The release of these compounds from their ‘main storage’ compartment depends on the blood flow through this compartment during sampling. Different sampling protocols (with or without exertion of an effort, or during increased blood flow through intestinal part of the body due to digestion processes after a meal, etc) lead to different concentrations of VOCs. Measurements with different sampling protocols could be done for an arbitrary VOC and, in particular, for the 112 cancer-related VOCs mentioned above. In this context, lung and upper airways cancer cells hold a distinguished status as due to their anatomic location, which allow them to release cancer-related VOCs directly into the exhaled air. Thus, the breath levels of these species can be enriched as compared to the levels expected from their blood concentrations. Consequently, the breath and blood concentrations of these volatile cancer markers cannot easily be related using e.g. the Farhi equation. Nevertheless, from the breath analysis point of view, the location of these cancers is beneficial as their VOCs’ fingerprints can be directly detected.

Detailed investigations and even *real-time* analysis should be possible for many of these 112 cancer VOCs in the foreseeable future. While all of these 112 compounds are the result of empirical studies, additional important aspects that would be needed for the connection of such compounds to logical metabolic processes. By doing so, one could biologically relate the concentrations emitted in breath, to concentrations in the different body compartments, and thus suggest indication for the disease development status. From a technological point of view it would be wanted to specify certain threshold concentrations of VOCs in breath to guide changes in the clinical treatment. This would result in a therapeutic monitoring guided by the exhaled concentrations of volatiles. By adapting the analytical and nano-technology in this direction one can achieve an on-line response by physicians.

4 Conclusions

The 112 volatile cancer biomarkers published during the last decade have very different physicochemical properties. Up to now, no advantage has been drawn from this fact. In this review, we showed that the blood:breath and blood:fat partition coefficients are very different for the 112 cancer-related VOCs. Even if the concentration of these 112 compounds would be identical in exhaled breath (e.g., 1 ppb), the respective concentrations in blood and in the fat compartment would vary, respectively, over 12 and 8 orders of magnitude. This means that different compounds may be stored (or exist in equilibrium) in different compartments of the body. To gain a more comprehensive understanding on the cancer-related VOCs, a combined information on appearance and concentration of these VOCs in breath and blood [1], or in breath and urine or saliva, is critical [138]. Further information can be achieved by investigating exhaled breath *and* resected tumor tissue from the same patient [11, 30]. For a simple point of care screening tool, knowing the exhalation kinetics and optimization of the sampling procedure is important. For research and eventual pharmaceutical treatment also the understanding of blood and tissue concentration would be critical.

Acknowledgments

AA gratefully appreciates funding from the Oncotyrol-project 2.1.1. The Competence Centre Oncotyrol is funded within the scope of the COMET—Competence Centers for Excellent Technologies through BMVIT, BMWFJ,

through the province of Salzburg and the Tiroler Zukunftsstiftung/Standortagentur Tirol. The COMET Program is conducted by the Austrian Research Promotion Agency (FFG). PM acknowledges support from the Austrian Science Fund (FWF) under grant no. P24736-B23. VR gratefully acknowledges a Lise-Meitner fellowship from the Austrian Science Fund (FWF) under grant no. M1213-B18. AA and VR appreciate funding from the Austrian Agency for International Cooperation in Education and Research (OeAD-GmbH, project SPA 04/158-FEM_PERS). AA, PM and VR thank the government of Vorarlberg (Austria) for its generous support. HH gratefully acknowledges the funding from the FP7-Health Program under the LCAOS (grant agreement no. 258868) and the FP7's ERC grant under DIAG-CANCER (grant agreement no. 256639).

References

- [1]. Mochalski P, King J, Klieber M, Unterkofler K, Hinterhuber H, Baumann M, Amann A. Blood and breath levels of selected volatile organic compounds in healthy volunteers. *Analyst*. 2013; 138:2134–45. [PubMed: 23435188]
- [2]. Filipiak W, Sponring A, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 *in vitro*. *Cancer Cell Int*. 2008; 8:17. [PubMed: 19025629]
- [3]. Sponring A, Filipiak W, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. Release of volatile organic compounds from the lung cancer cell line NCI-H2087 *in vitro*. *Anticancer Res*. 2009; 29:419–26. [PubMed: 19331181]
- [4]. Sponring A, Filipiak W, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. *Cancer Biomarkers A*. 2010; 7:153–61.
- [5]. Barash O, Peled N, Hirsch FR, Haick H. Sniffing the unique 'odor print' of non-small-cell lung cancer with gold nanoparticles. *Small*. 2009; 5:2618–24. [PubMed: 19705367]
- [6]. Filipiak W, Sponring A, Filipiak A, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells *in vitro*. *Cancer Epidemiol Biomarkers Prev*. 2010; 19:182–95. [PubMed: 20056637]
- [7]. Amal H, et al. The scent fingerprint of hepatocarcinoma: *in-vitro* metastasis prediction with volatile organic compounds (VOCs). *Int J Nanomed*. 2012; 7:4135–46.
- [8]. Barash O, Peled N, Tisch U, Bunn PA Jr, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. *Nanomedicine*. 2012; 8:580–9. [PubMed: 22033081]
- [9]. Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA Jr, Hirsch FR, Haick H. Volatile fingerprints of cancer specific genetic mutations. *Nanomedicine*. 2013; 9:758–66. [PubMed: 23428987]
- [10]. Mochalski P, Sponring A, King J, Unterkofler K, Troppmair J, Amann A. Release and uptake of volatile organic compounds by human hepatocellular carcinoma cells (HepG2) *in vitro*. *Cancer Cell Int*. 2013; 13:72. [PubMed: 23870484]
- [11]. Filipiak W, et al. Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath markers submitted. 2013
- [12]. Amann A, Poupart G, Telser S, Ledochowski M, Schmid A, Mechtcheriakov S. Applications of breath gas analysis in medicine. *Int J Mass Spectrom*. 2004; 239:227–33.
- [13]. Baumbach, JI.; Vautz, W.; Ruzsanyi, V.; Freitag, L. Metabolites in human breath: ion mobility spectrometers as diagnostic tools for lung diseases. *Breath Analysis: for Clinical Diagnosis and Therapeutic Monitoring*. Amann, A.; Smith, D., editors. Singapore: World Scientific; 2005. p. 53–66.
- [14]. Buszewski B, Keszy M, Ligor T, Amann A. Human exhaled air analytics: biomarkers of diseases. *Biomed Chromatogr*. 2007; 21:553–66. [PubMed: 17431933]
- [15]. Amann, A.; Smith, D., editors. *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine*. Amsterdam: Elsevier; 2013.
- [16]. Solga, S.; Risby, T. Issues and challenges in human breath research: perspectives from our experience. *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine*. Amann, A.; Smith, D., editors. Amsterdam: Elsevier; 2013. p. 19–24.

- [17]. Pleil JD, Stiegel MA, Risby TH. Clinical breath analysis: discriminating between human endogenous compounds and exogenous (environmental) chemical confounders. *J Breath Res.* 2013; 7:017107. [PubMed: 23445880]
- [18]. Haick H, Broza Y, Mochalski P, Ruzsanyi V, Amann A. Assessment, origin, and implementation of breath volatile cancer markers. *Chem Soc Rev.* 2014; 43:1423–49. [PubMed: 24305596]
- [19]. Konvalina G, Haick H. Sensors for breath testing: from nanomaterials to comprehensive disease detection. *Acc Chem Res.* 2014; 47:66–76. [PubMed: 23926883]
- [20]. Broza YY, Haick H. Nanomaterial-based sensors for detection of disease by volatile organic compounds. *Nanomedicine (Lond).* 2013; 8:785–806. [PubMed: 23656265]
- [21]. Tisch, U.; Haick, H. Arrays of nanomaterial-based sensors for breath testing. *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine.* Amann, A.; Smith, D., editors. Amsterdam: Elsevier; 2013.
- [22]. Tisch U, Haick H. Arrays of chemisensitive monolayer-capped metallic nanoparticles for diagnostic breath testing. *Rev Chem Eng.* 2010; 26:171–9.
- [23]. Tisch U, Haick H. Nanomaterials for cross-reactive sensor arrays. *MRS Bull.* 2010; 35:797–803.
- [24]. Leja MA, Liu H, Haick H. Breath testing: the future for digestive cancer detection. *Expert Rev Gastroenterol Hepatol.* 2013; 7:389–91. [PubMed: 23899275]
- [25]. Trefz P, Schmidt M, Oertel P, Obermeier J, Brock B, Kamysek S, Dunkl J, Zimmermann R, Schubert JK, Miekisch W. Continuous real time breath gas monitoring in the clinical environment by proton-transfer-reaction-time-of-flight-mass spectrometry. *Anal Chem.* 2013; 85:10321–9. [PubMed: 24044609]
- [26]. Filipiak W, et al. Pathogen-derived breath markers for monitoring of lower respiratory tract infections in mechanically ventilated patients submitted. 2013
- [27]. Kazui M, Andreoni KA, Williams GM, Perler BA, Bulkley GB, Beattie C, Donham RT, Sehnert SS, Burdick JF, Risby TH. Visceral lipid peroxidation occurs at reperfusion after supraceliac aortic cross-clamping. *J Vasc Surg.* 1994; 19:473–7. [PubMed: 8126860]
- [28]. Pabst F, Miekisch W, Fuchs P, Kischkel S, Schubert JK. Monitoring of oxidative and metabolic stress during cardiac surgery by means of breath biomarkers: an observational study. *J Cardiothorac Surg.* 2007; 2:37. [PubMed: 17877828]
- [29]. Brown RH, Wagner EM, Cope KA, Risby TH. Propofol and *in vivo* oxidative stress: effects of preservative. *J Breath Res.* 2009; 3:016003. [PubMed: 21383451]
- [30]. Broza YY, Kremer R, Tisch U, Gevorkyan A, Shiban A, Best LA, Haick H. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. *Nanomedicine (New York).* 2013; 9:15–21.
- [31]. Filipiak W, Sponring A, Baur MM, Ager C, Filipiak A, Wiesenhofer H, Nagl M, Troppmair J, Amann A. Characterization of volatile metabolites taken up by or released from *Streptococcus pneumoniae* and *Haemophilus influenzae* by using GC-MS. *Microbiology.* 2012; 158:3044–53. [PubMed: 23059976]
- [32]. Filipiak W, Sponring A, Baur MM, Filipiak A, Ager C, Wiesenhofer H, Nagl M, Troppmair J, Amann A. Molecular analysis of volatile metabolites released specifically by *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *BMC Microbiol.* 2012; 12:113. [PubMed: 22716902]
- [33]. Filipiak, W.; Sponring, A.; Filipiak, A.; Baur, MM.; Ager, C.; Wiesenhofer, H.; Margesin, R.; Nagl, M.; Troppmair, J.; Amann, A. Volatile organic compounds (VOCs) released by pathogenic microorganisms *in vitro*: potential breath biomarkers for early-stage diagnosis of disease. *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine.* Amann, A.; Smith, D., editors. Amsterdam: Elsevier; 2013. p. 463-512.
- [34]. Zhu J, Jimenez-Diaz J, Bean HD, Daphtary NA, Aliyeva MI, Lundblad LK, Hill JE. Robust detection of *P. aeruginosa* and *S. aureus* acute lung infections by secondary electrospray ionization-mass spectrometry (SESI-MS) breathprinting: from initial infection to clearance. *J Breath Res.* 2013; 7:037106. [PubMed: 23867706]
- [35]. Zhu J, Bean HD, Wargo MJ, Leclair LW, Hill JE. Detecting bacterial lung infections: *in vivo* evaluation of *in vitro* volatile fingerprints. *J Breath Res.* 2013; 7:016003. [PubMed: 23307645]

- [36]. Tuboly E, Szabo A, Eros G, Mohacsi A, Szabo G, Tengolics R, Rakhely G, Boros M. Determination of endogenous methane formation by photoacoustic spectroscopy. *J Breath Res.* 2013; 7:046004. [PubMed: 24185326]
- [37]. Eisenmann A, Amann A, Said M, Datta B, Ledochowski M. Implementation and interpretation of hydrogen breath tests. *J Breath Res.* 2008; 2:046002. [PubMed: 21386189]
- [38]. de Lacy Costello BP, Ledochowski M, Ratcliffe NM. The importance of methane breath testing: a review. *J Breath Res.* 2013; 7:024001. [PubMed: 23470880]
- [39]. Erhart S, et al. 3-Heptanone as a potential new marker for valproic acid therapy. *J Breath Res.* 2009; 3:016004. [PubMed: 21383452]
- [40]. Modak A. Breath tests with ^{13}C substrates. *J Breath Res.* 2009; 3:040201. [PubMed: 21386144]
- [41]. Modak AS. Single time point diagnostic breath tests: a review. *J Breath Res.* 2010; 4:017002. [PubMed: 21386204]
- [42]. Wagner DA, Schatz R, Coston R, Curington C, Bolt D, Toskes PP. A new ^{13}C breath test to detect vitamin B12 deficiency: a prevalent and poorly diagnosed health problem. *J Breath Res.* 2011; 5:046001. [PubMed: 21697586]
- [43]. Rubin T, von Haimberger T, Helmke A, Heyne K. Quantitative determination of metabolism dynamics by a real-time $^{13}\text{CO}_2$ breath test. *J Breath Res.* 2011; 5:027102. [PubMed: 21502704]
- [44]. Thacker DL, Modak A, Flockhart DA, Desta Z. Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? *J Breath Res.* 2013; 7:016001. [PubMed: 23257668]
- [45]. Modak AS. Regulatory issues on breath tests and updates of recent advances on [13C]-breath tests. *J Breath Res.* 2013; 7:037103. [PubMed: 23774086]
- [46]. Ruzsanyi V, Mochalski P, Schmid A, Wiesenhofer H, Klieber M, Hinterhuber H, Amann A. Ion mobility spectrometry for detection of skin volatiles. *J Chromatogr B, Anal Technol Biomed Life Sci.* 2012; 911:84–92.
- [47]. Schmidt FM, Vaittinen O, Metsala M, Lehto M, Forsblom C, Groop PH, Halonen L. Ammonia in breath and emitted from skin. *J Breath Res.* 2013; 7:017109. [PubMed: 23445955]
- [48]. Mochalski P, Krapf K, Ager C, Wiesenhofer H, Agapiou A, Statheropoulos M, Fuchs D, Ellmerer E, Buszewski B, Amann A. Temporal profiling of human urine VOCs and its potential role under the ruins of collapsed buildings. *Toxicol Mech Methods.* 2012; 22:502–11. [PubMed: 22482743]
- [49]. Al-Kateb H, de Lacy Costello B, Ratcliffe N. An investigation of volatile organic compounds from the saliva of healthy individuals using headspace-trap/GC-MS. *J Breath Res.* 2013; 7:036004. [PubMed: 23867616]
- [50]. ten Oever J, Mandon J, Netea MG, van Deuren M, Harren FJ, Cristescu SM, Pickkers P. Pulmonary infection, and not systemic inflammation, accounts for increased concentrations of exhaled nitric oxide in patients with septic shock. *J Breath Res.* 2013; 7:036003. [PubMed: 23867579]
- [51]. Tarnoki DL, et al. Genetic influence on the relation between exhaled nitric oxide and pulse wave reflection. *J Breath Res.* 2013; 7:026008. [PubMed: 23660450]
- [52]. Hirano T, Matsunaga K, Sugiura H, Minakata Y, Koarai A, Akamatsu K, Ichikawa T, Furukawa K, Ichinose M. Relationship between alveolar nitric oxide concentration in exhaled air and small airway function in COPD. *J Breath Res.* 2013; 7:046002. [PubMed: 24091810]
- [53]. Heffler E, Pizzimenti S, Badiu I, Guida G, Ricciardolo FL, Bucca C, Rolla G. Nasal nitric oxide is a marker of poor asthma control. *J Breath Res.* 2013; 7:026009. [PubMed: 23665726]
- [54]. Cristescu SM, Mandon J, Harren FJ, Merilainen P, Hogman M. Methods of NO detection in exhaled breath. *J Breath Res.* 2013; 7:017104. [PubMed: 23445766]
- [55]. Boshier PR, Hanna GB, Marczin N. Exhaled nitric oxide as biomarker of acute lung injury: an unfulfilled promise? *J Breath Res.* 2013; 7:017118. [PubMed: 23445570]
- [56]. Horvath I, Dweik R, Barnes PJ. Exhaled nitric oxide comes of age. *J Breath Res.* 2012; 6:040201. [PubMed: 23186829]
- [57]. Högman M. Extended NO analysis in health and disease. *J Breath Res.* 2012; 6:047103. [PubMed: 22677778]

- [58]. Bucca C, Cicolin A, Guida G, Heffler E, Brussino L, Rolla G. Exhaled nitric oxide (FENO) in non-pulmonary diseases. *J Breath Res.* 2012; 6:027104. [PubMed: 22549131]
- [59]. Shorter JH, Nelson DD, McManus JB, Zahniser MS, Sama SR, Milton DK. Clinical study of multiple breath biomarkers of asthma and COPD (NO, CO₂, CO and N₂O) by infrared laser spectroscopy. *J Breath Res.* 2011; 5:037108. [PubMed: 21757803]
- [60]. McCurdy MR, Sharafkhaneh A, Abdel-Monem H, Rojo J, Tittel FK. Exhaled nitric oxide parameters and functional capacity in chronic obstructive pulmonary disease. *J Breath Res.* 2011; 5:016003. [PubMed: 21378438]
- [61]. Magori E, Hiltawsky K, Fleischer M, Simon E, Pohle R, von Sicard O, Tawil A. Fractional exhaled nitric oxide measurement with a handheld device. *J Breath Res.* 2011; 5:027104. [PubMed: 21646688]
- [62]. Ryter SW, Choi AM. Carbon monoxide in exhaled breath testing and therapeutics. *J Breath Res.* 2013; 7:017111. [PubMed: 23446063]
- [63]. Agapiou A, Mikedi K, Karma S, Giotaki ZK, Kolostoumbis D, Papageorgiou C, Zorba E, Spiliopoulou C, Amann A, Statheropoulos M. Physiology and biochemistry of human subjects during entrapment. *J Breath Res.* 2013; 7:016004. [PubMed: 23318246]
- [64]. Agapiou, A.; Mochalski, P.; Schmid, A.; Amann, A. Potential applications of volatile organic compounds in safety and security. *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine*. Amann, A.; Smith, D., editors. Amsterdam: Elsevier; 2013. p. 515-58.
- [65]. Amann A, et al. Analysis of exhaled breath for screening of lung cancer patients. *Mag Eur Med Oncol.* 2010; 3:106–12.
- [66]. Amann A, Corradi M, Mazzone P, Mutti A. Lung cancer biomarkers in exhaled breath. *Expert Rev Mol Diagn.* 2011; 11:207–17. [PubMed: 21405971]
- [67]. Hakim M, Broza YY, Barash O, Peled N, Phillips M, Amann A, Haick H. Volatile organic compounds of lung cancer and possible biochemical pathways. *Chem Rev.* 2012; 112:5949–66. [PubMed: 22991938]
- [68]. Amann, A.; Telser, S.; Hofer, L.; Schmid, A.; Hinterhuber, H. Exhaled breath gas as a biochemical probe during sleep. *Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring*. Amann, A.; Smith, D., editors. Singapore: World Scientific; 2005. p. 305-16.
- [69]. King J, Kupferthaler A, Unterkofler K, Koc H, Teschl S, Teschl G, Miekisch W, Schubert J, Hinterhuber H, Amann A. Isoprene and acetone concentration profiles during exercise on an ergometer. *J Breath Res.* 2009; 3:027006. [PubMed: 21383461]
- [70]. King J, Mochalski P, Kupferthaler A, Unterkofler K, Koc H, Filipiak W, Teschl S, Hinterhuber H, Amann A. Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study. *Physiol Meas.* 2010; 31:1169–84. [PubMed: 20664160]
- [71]. King J, Unterkofler K, Teschl G, Teschl S, Mochalski P, Koc H, Hinterhuber H, Amann A. A modeling-based evaluation of isothermal rebreathing for breath gas analyses of highly soluble volatile organic compounds. *J Breath Res.* 2012; 6:016005. [PubMed: 22233667]
- [72]. King J, Kupferthaler A, Frauscher B, Hackner H, Unterkofler K, Teschl G, Hinterhuber H, Amann A, Hög B. Measurement of endogenous acetone and isoprene in exhaled breath during sleep. *Physiol Meas.* 2012; 33:413–28. [PubMed: 22370046]
- [73]. Winkler K, Herbig J, Kohl I. Real-time metabolic monitoring with proton transfer reaction mass spectrometry. *J Breath Res.* 2013; 7:036006. [PubMed: 23959812]
- [74]. White IR, Willis KA, Whyte C, Cordell R, Blake RS, Wardlaw AJ, Rao S, Grigg J, Ellis AM, Monks PS. Real-time multi-marker measurement of organic compounds in human breath: towards fingerprinting breath. *J Breath Res.* 2013; 7:017112. [PubMed: 23446116]
- [75]. Mochalski P, Rudnicka J, Agapiou A, Statheropoulos M, Amann A, Buszewski B. Near real-time VOCs analysis using an aspiration ion mobility spectrometer. *J Breath Res.* 2013; 7:026002. [PubMed: 23470292]
- [76]. Kohl I, et al. First observation of a potential non-invasive breath gas biomarker for kidney function. *J Breath Res.* 2013; 7:017110. [PubMed: 23446042]
- [77]. Amann A, King J, Kupferthaler A, Unterkofler K, Koc H, Teschl S, Hinterhuber H. Exhaled breath analysis—quantifying the storage of lipophilic compounds in the human body. *Proc Ecolpo.* 2009; 3:9–13.

- [78]. King J, Koc H, Unterkofler K, Mochalski P, Kupferthaler A, Teschl G, Teschl S, Hinterhuber H, Amann A. Physiological modeling of isoprene dynamics in exhaled breath. *J Theor Biol.* 2010; 267:626–37. [PubMed: 20869370]
- [79]. Koc H, King J, Teschl G, Unterkofler K, Teschl S, Mochalski P, Hinterhuber H, Amann A. The role of mathematical modeling in VOC analysis using isoprene as a prototypic example. *J Breath Res.* 2011; 5:037102. [PubMed: 21654024]
- [80]. King J, Unterkofler K, Teschl G, Teschl S, Koc H, Hinterhuber H, Amann A. A mathematical model for breath gas analysis of volatile organic compounds with special emphasis on acetone. *J Math Biol.* 2011; 63:959–99. [PubMed: 21234569]
- [81]. King J, Unterkofler K, Teschl S, Amann A, Teschl G. Breath gas analysis for estimating physiological processes using anesthetic monitoring as a prototypic example. *Conf Proc: Annu Int Conf of the IEEE Engineering in Medicine and Biology Society (2011).* 2011:1001–4.
- [82]. King, J.; Koc, H.; Unterkofler, K.; Teschl, G.; Teschl, S.; Mochalski, P.; Hinterhuber, H.; Amann, A. Physiological modeling for analysis of exhaled breath. *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine.* Amann, A.; Smith, D., editors. Amsterdam: Elsevier; 2013. p. 27–46.
- [83]. Kohl, I.; Herbig, J.; Dunkl, J.; Hansel, A.; Daniaux, M.; Hubalek, M. Smokers breath as seen by proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF-MS). *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine.* Amann, A.; Smith, D., editors. Amsterdam: Elsevier; 2013.
- [84]. Kushch I, et al. Breath isoprene—aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. *Clin Chem Lab Med.* 2008; 46:1011–8. [PubMed: 18605961]
- [85]. Conkle JP, Camp BJ, Welch BE. Trace composition of human respiratory gas. *Arch Environ Health.* 1975; 30:290–5. [PubMed: 1137435]
- [86]. Jansson BO, Larsson BT. Analysis of organic compounds in human breath by gas chromatography-mass spectrometry. *J Lab Clin Med.* 1969; 74:961–6. [PubMed: 5359667]
- [87]. Gelmont D, Stein RA, Mead JF. Isoprene—the main hydrocarbon in human breath. *Biochem Biophys Res Commun.* 1981; 99:1456–60. [PubMed: 7259787]
- [88]. Bajtarevic A, et al. Noninvasive detection of lung cancer by analysis of exhaled breath. *BMC Cancer.* 2009; 9:348. [PubMed: 19788722]
- [89]. Kohl I, Dunkl J, Herbig J, Hubalek M, Fiegl H, Daniaux M. Zukunft des brustkrebscreenings—atemgasanalyse für eine zukünftige nicht-invasive medizin. *Gynäkol Onkol.* 2012; 6:21.
- [90]. Fuchs D, Jamnig H, Heiningner P, Klieber M, Schroecksnadel S, Fiegl M, Hackl M, Denz H, Amann A. Decline of exhaled isoprene in lung cancer patients correlates with immune activation. *J Breath Res.* 2012; 6:027101. [PubMed: 22427487]
- [91]. King J, Mochalski P, Unterkofler K, Teschl G, Klieber M, Stein M, Amann A, Baumann M. Breath isoprene: muscle dystrophy patients support the concept of a pool of isoprene in the periphery of the human body. *Biochem Biophys Res Commun.* 2012; 423:526–30. [PubMed: 22683640]
- [92]. Amann, A.; Miekisch, W.; Pleil, J.; Risby, T.; Schubert, W. Methodological issues of sample collection and analysis of exhaled breath. *European Respiratory Society Monograph 49.* Horvath, I.; de Jongste, JC., editors. Lausanne: European Respiratory Society; 2010. p. 96–114.
- [93]. Farhi LE. Elimination of inert gas by the lung. *Respir Physiol.* 1967; 3:1–11. [PubMed: 6059100]
- [94]. Mochalski P, King J, Kupferthaler A, Unterkofler K, Hinterhuber H, Amann A. Measurement of isoprene solubility in water, human blood and plasma by multiple headspace extraction gas chromatography coupled with solid phase microextraction. *J Breath Res.* 2011; 5:046010. [PubMed: 22071957]
- [95]. Mochalski P, King J, Kupferthaler A, Unterkofler K, Hinterhuber H, Amann A. Human blood and plasma partition coefficients for C4–C8 n-alkanes, isoalkanes, and 1-alkenes. *Int J Toxicol.* 2012; 31:267–75. [PubMed: 22674932]
- [96]. Filser JG, Csanady GA, Denk B, Hartmann M, Kauffmann A, Kessler W, Kreuzer PE, Putz C, Shen JH, Stei P. Toxicokinetics of isoprene in rodents and humans. *Toxicology.* 1996; 113:278–87. [PubMed: 8901909]

- [97]. Mork AK, Johanson G. A human physiological model describing acetone kinetics in blood and breath during various levels of physical exercise. *Toxicol Lett.* 2006; 164:6–15. [PubMed: 16364574]
- [98]. Perbellini L, Brugnone F, Caretta D, Maranelli G. Partition coefficients of some industrial aliphatic hydrocarbons (C5-C7) in blood and human tissues. *Br J Indust Med.* 1985; 42:162–7.
- [99]. Fiserova-Bergerova V, Diaz ML. Determination and prediction of tissue-gas partition coefficients. *Int Arch Occup Environ Health.* 1986; 58:75–87. [PubMed: 3721592]
- [100]. Zahlsen K, Eide I, Nilsen AM, Nilsen OG. Inhalation kinetics of C8 to C10 1-alkenes and iso-alkanes in the rat after repeated exposures. *Pharm Toxicol.* 1993; 73:163–8.
- [101]. Balaz S, Lukacova V. A model-based dependence of the human tissue/blood partition coefficients of chemicals on lipophilicity and tissue composition. *Quant Struct-Act Relat.* 1999; 18:361–8.
- [102]. Meulenberg CJ, Vijverberg HP. Empirical relations predicting human and rat tissue:air partition coefficients of volatile organic compounds. *Toxicol Appl Pharm.* 2000; 165:206–16.
- [103]. Licata AC, Dekant W, Smith CE, Borghoff SJ. A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses. *Toxicol Sci.* 2001; 62:191–204. [PubMed: 11452131]
- [104]. Thrall KD, Gies RA, Muniz J, Woodstock AD, Higgins G. Route-of-entry and brain tissue partition coefficients for common superfund contaminants. *J Toxicol Environ Health A.* 2002; 65:2075–86. [PubMed: 12515587]
- [105]. Abraham MH, Ibrahim A, Acree WE Jr. Air to blood distribution of volatile organic compounds: a linear free energy analysis. *Chem Res Toxicol.* 2005; 18:904–11. [PubMed: 15892585]
- [106]. Abraham MH, Ibrahim A. Air to fat and blood to fat distribution of volatile organic compounds and drugs: linear free energy analyses. *Eur J Med Chem.* 2006; 41:1430–8. [PubMed: 16996652]
- [107]. Poulin P, Krishnan K. An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data. *J Toxicol Environ Health.* 1995; 46:117–29. [PubMed: 7666490]
- [108]. Sander, R. Compilation of Henry's law constants for inorganic and organic species of potential importance in environmental chemistry. 1999. www.mpch-mainz.mpg.de/%7Esander/res/henry.html
- [109]. Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca Michele, Mutti A. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. *Respir Res.* 2005; 6:71. [PubMed: 16018807]
- [110]. Xue R, Dong L, Zhang S, Deng C, Liu T, Wang J, Shen X. Investigation of volatile biomarkers in liver cancer blood using solid-phase microextraction and gas chromatography/mass spectrometry. *Rapid Commun Mass Spectrom.* 2008; 22:1181–6. [PubMed: 18350562]
- [111]. Phillips M, Cataneo RN, Ditzkoff BA, Fisher P, Greenberg J, Gunawardena R, Kwon CS, Rahbari-Oskoui F, Wong C. Volatile markers of breast cancer in the breath. *Breast J.* 2003; 9:184–91. [PubMed: 12752626]
- [112]. Phillips M, Cataneo RN, Saunders C, Hope P, Schmitt P, Wai J. Volatile biomarkers in the breath of women with breast cancer. *J Breath Res.* 2010; 4:026003. [PubMed: 21383471]
- [113]. Gaspar EM, Lucena AF, Duro da Costa J, Chaves das Neves H. Organic metabolites in exhaled human breath—a multivariate approach for identification of biomarkers in lung disorders. *J Chromatogr A.* 2009; 1216:2749–56. [PubMed: 19036381]
- [114]. Hakim M, Billan S, Tisch U, Peng G, Dvorkind I, Marom O, Abdah-Bortnyak R, Kuten A, Haick H. Diagnosis of head and neck cancer from exhaled breath. *Br J Cancer.* 2011; 104:1649–55. [PubMed: 21505455]
- [115]. Peng G, Hakim M, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Tisch U, Haick H. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. *Br J Cancer.* 2010; 103:542–51. [PubMed: 20648015]
- [116]. Phillips M, Altorki N, Austin JHM, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A. Detection of lung cancer using weighted digital analysis of breath biomarkers. *Clin Chim Acta.* 2008; 393:76–84. [PubMed: 18420034]

- [117]. Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, Kwon SC, Tietje O, Wong C. Prediction of breast cancer using volatile biomarkers in the breath. *Breast Cancer Res Treat.* 2006; 99:19–21. [PubMed: 16502014]
- [118]. Song G, Qin T, Liu H, Xu GB, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD. Quantitative breath analysis of volatile organic compounds of lung cancer patients. *Lung Cancer.* 2010; 67:227–31. [PubMed: 19409642]
- [119]. Fuchs P, Loesecken C, Schubert JK, Miekisch W. Breath gas aldehydes as biomarkers of lung cancer. *Int J Cancer.* 2010; 126:2663–70. [PubMed: 19839051]
- [120]. Phillips M, Altorki N, Austin JHM, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI. Prediction of lung cancer using volatile biomarkers in breath. *Cancer Biomarkers.* 2007; 3:95–109. [PubMed: 17522431]
- [121]. Xu ZQ, et al. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. *Br J Cancer.* 2013; 108:941–50. [PubMed: 23462808]
- [122]. Zou Y, Wang L, Zhao C, Hu Y, Xu S, Ying K, Wang P, Chen X. CEA, SCC and NSE levels in exhaled breath condensate-possible markers for early detection of lung cancer. *J Breath Res.* 2013; 7:047101. [PubMed: 24185583]
- [123]. Filipiak W, et al. Dependence of exhaled breath composition on exogenous factors, smoking habits and exposure to air pollutants. *J Breath Res.* 2012; 6:036008. [PubMed: 22932429]
- [124]. Moretti M, Phillips M, Abouzeid A, Cataneo RN, Greenberg J. Increased breath markers of oxidative stress in normal pregnancy and in preeclampsia. *Am J Obstet Gynecol.* 2004; 190:1184–90. [PubMed: 15167816]
- [125]. Phillips M, et al. Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). *J Heart Lung Transplant.* 2004; 23:701–8. [PubMed: 15366430]
- [126]. Phillips M, Cataneo RN, Cheema T, Greenberg J. Increased breath biomarkers of oxidative stress in diabetes mellitus. *Clin Chim Acta.* 2004; 344:189–94. [PubMed: 15149888]
- [127]. Phillips M, Cataneo RN, Greenberg J, Grodman R, Gunawardena R, Naidu A. Effect of oxygen on breath markers of oxidative stress. *Eur Respir J.* 2003; 21:48–51. [PubMed: 12570108]
- [128]. Phillips M, Cataneo RN, Greenberg J, Grodman R, Salazar M. Breath markers of oxidative stress in patients with unstable angina. *Heart Dis.* 2003; 5:95–9. [PubMed: 12713676]
- [129]. Phillips M, Cataneo RN, Greenberg J, Gunawardena R, Naidu A, Rahbari-Oskoui F. Effect of age on the breath methylated alkane contour, a display of apparent new markers of oxidative stress. *J Lab Clin Med.* 2000; 136:243–9. [PubMed: 10985503]
- [130]. Phillips M, Cataneo RN, Greenberg J, Gunawardena R, Rahbari-Oskoui F. Increased oxidative stress in younger as well as in older humans. *Clin Chim Acta.* 2003; 328:83–6. [PubMed: 12559601]
- [131]. De Lacy Costello, B.; Ratcliffe, NM. Volatile organic compounds (VOCs) found in urine and stool. *Volatile Biomarkers: Non-invasive Diagnosis in Physiology and Medicine.* Amann, A.; Smith, D., editors. Amsterdam: Elsevier; 2013.
- [132]. Penn DJ, Oberzaucher E, Grammer K, Fischer G, Soini HA, Wiesler D, Novotny MV, Dixon SJ, Xu Y, Brereton RG. Individual and gender fingerprints in human body odour. *J R Soc Interface.* 2007; 4:331–40. [PubMed: 17251141]
- [133]. Soini HA, Klouckova I, Wiesler D, Oberzaucher E, Grammer K, Dixon SJ, Xu Y, Brereton RG, Penn DJ, Novotny MV. Analysis of volatile organic compounds in human saliva by a static sorptive extraction method and gas chromatography-mass spectrometry. *J Chem Ecol.* 2010; 36:1035–42. [PubMed: 20809147]
- [134]. Phillips M, et al. Detection of lung cancer using weighted digital analysis of breath biomarkers. *Clin Chim Acta.* 2008; 393:76–84. [PubMed: 18420034]
- [135]. Soini HA, Bruce KE, Klouckova I, Brereton RG, Penn DJ, Novotny MV. *In situ* surface sampling of biological objects and preconcentration of their volatiles for chromatographic analysis. *Anal Chem.* 2006; 78:7161–8. [PubMed: 17037916]
- [136]. Kostelc JG, Preti G, Zelson PR, Tonzetich J, Huggins GR. Volatiles of exogenous origin from the human oral cavity. *J Chromatogr.* 1981; 226:315–23. [PubMed: 7320162]
- [137]. Mochalski P, Unterkofler K, Hinterhuber H, Amann A. Emission of volatile organic compounds from skin of healthy volunteers submitted. 2013

- [138]. de Lacy Costello B, Amann A, Al-Kateb H, Flynn C, Filipiak W, Ratcliffe NM. A review of the volatiles from the healthy human body. *J Breath Res.* 2013; 8:014001. [PubMed: 24421258]
- [139]. Rieder J, Lirk P, Ebenbichler C, Gruber G, Prazeller P, Lindinger W, Amann A. Analysis of volatile organic compounds: possible applications in metabolic disorders and cancer screening. *Wien Klin Wochenschr.* 2001; 113:181–5. [PubMed: 11293947]

Figure 1.

Output of isoprene (nmol min^{-1}), acetone (arbitrary units) and CO_2 (L min^{-1}) for a healthy volunteer during rest phases and exertion of an effort of 75 W on a stationary bicycle. In case of CO_2 , 15 exhalations per minute with 3 L of alveolar air with 4% of CO_2 correspond to 1.8 L min^{-1} of CO_2 ($= 15 \cdot 3 \cdot 0.04 \text{ L min}^{-1}$). Isoprene output through exhaled breath may increase up to a factor ~ 10 during exertion of an effort, whereas the concentration in breath increases up to a factor ~ 5 . In this experiment, two steady-states of isoprene exhalation appear, (A) at $\sim 25 \text{ nmol min}^{-1}$ (corresponding to production of isoprene in the liver) and (B) at $\sim 100 \text{ nmol L}^{-1}$ (corresponding to production of isoprene in the muscles). In a person with high cholesterol blood level, the production of isoprene in the liver would be decreased under the influence of statins [139]. Reproduced with permission from [69], © 2009 IOP Publishing.

Figure 2.

Partition coefficient, $-\log(\lambda_{b:a})$, for 112 volatile cancer biomarkers published during the last decade [7, 30, 67, 109–121], as well as acetone and 2-pentanone for comparison. The color for the different compound names is chosen according to the chemical class. Compounds with a higher $\log(\lambda_{b:a})$ will tend to be in the blood and vice versa.

Figure 3.

Partition coefficient, $-\log(\lambda_{f:b})$, for 112 volatile cancer biomarkers published during the last decade [7, 30, 67, 109–121], as well as acetone and 2-pentanone for comparison. The color for the different compound names is chosen according to the chemical class. Compounds with a higher $\log(\lambda_{f:b})$ will tend to be in the fat and vice versa.